相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency
Chun-Hwei Tai et al.
MOLECULAR THERAPY (2022)
Addressing high dose AAV toxicity - 'one and done' or 'slower and lower'?
Takashi Kei Kishimoto et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Human and Insect Cell-Produced Recombinant Adeno-Associated Viruses Show Differences in Genome Heterogeneity
Ngoc Tam Tran et al.
HUMAN GENE THERAPY (2022)
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
M. C. Ozelo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Evaluating the state of the science for adeno-associated virus integration: An integrated perspective
Denise E. Sabatino et al.
MOLECULAR THERAPY (2022)
A versatile toolkit for overcoming AAV immunity
Xuefeng Li et al.
FRONTIERS IN IMMUNOLOGY (2022)
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
Barbara A. Konkle et al.
BLOOD (2021)
Overcoming innate immune barriers that impede AAV gene therapy vectors
Manish Muhuri et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell et al.
MOLECULAR THERAPY (2021)
Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe Disease
Yedda Li et al.
MOLECULAR THERAPY (2021)
A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells
Giang N. Nguyen et al.
NATURE BIOTECHNOLOGY (2021)
The clinical landscape for AAV gene therapies
Dmitry A. Kuzmin et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2021)
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa Chand et al.
JOURNAL OF HEPATOLOGY (2021)
Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles
Petr O. Ilyinskii et al.
SCIENCE ADVANCES (2021)
Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Alessia Amato et al.
FRONTIERS IN MEDICINE (2021)
Liver gene therapy and hepatocellular carcinoma: A complex web
Ype P. de Jong et al.
MOLECULAR THERAPY (2021)
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Bradley A. Hamilton et al.
FRONTIERS IN IMMUNOLOGY (2021)
T Cell-Mediated Immune Responses to AAV and AAV Vectors
Hildegund C. J. Ertl
FRONTIERS IN IMMUNOLOGY (2021)
Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
Thomas Weber
FRONTIERS IN IMMUNOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
SYSTEMATIC REVIEWS (2021)
AAV integration in human hepatocytes
Dhwanil A. Dalwadi et al.
MOLECULAR THERAPY (2021)
Encouraging and Unsettling Findings in Long-Term Follow-up of AAV Gene Transfer
Roland W. Herzog
MOLECULAR THERAPY (2020)
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Helena Costa Verdera et al.
MOLECULAR THERAPY (2020)
Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?
J. Fraser Wright
MOLECULAR THERAPY (2020)
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Giuseppe Ronzitti et al.
FRONTIERS IN IMMUNOLOGY (2020)
Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors
Neil G. Rumachik et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Moving Forward after Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
James M. Wilson et al.
Genetic Engineering & Biotechnology News (2020)
Re: Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy by Wilson and Flotte
Perry B. Shieh et al.
HUMAN GENE THERAPY (2020)
Quantification of CpG Motifs in rAAVGenomes: Avoiding the Toll
J. Fraser Wright
MOLECULAR THERAPY (2020)
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
Christian Mueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology
Juliette Hordeaux et al.
HUMAN GENE THERAPY (2020)
Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Zachary C. Elmore et al.
JCI INSIGHT (2020)
Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2
Dolan Sondhi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates
Juliette Hordeaux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
K. John Pasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier
Juliette Hordeaux et al.
MOLECULAR THERAPY (2019)
Adeno-associated virus vector as a platform for gene therapy delivery
Dan Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids
Qin Huang et al.
PLOS ONE (2019)
High levels of AAV vector integration into CRISPR-induced DNA breaks
Killian S. Hanlon et al.
NATURE COMMUNICATIONS (2019)
Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations
Charmaine A. Ramlogan-Steel et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Scott N. Ashley et al.
CELLULAR IMMUNOLOGY (2019)
ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome
Li Ou et al.
MOLECULAR THERAPY (2019)
Methylation Status of the Adeno-Associated Virus Type 2 (AAV2)
Renata Toth et al.
VIRUSES-BASEL (2019)
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
Christian Hinderer et al.
HUMAN GENE THERAPY (2018)
An Observational Study from Long-Term MV Re-administration in Two Hemophilia Dogs
Junjiang Sun et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial
Celine Vandamme et al.
HUMAN GENE THERAPY (2017)
Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells
Oleksandr Kondratov et al.
MOLECULAR THERAPY (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
L. A. George et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion
Longping Victor Tse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR+/- Rhesus Macaques
Jenny A. Greig et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2017)
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Benjamin E. Deverman et al.
NATURE BIOTECHNOLOGY (2016)
Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer
George Q. Perrin et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Nathalie Clement et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Randy J. Chandler et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Unique Roles of TLR9-and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer
Geoffrey L. Rogers et al.
JOURNAL OF INNATE IMMUNITY (2015)
Mechanism-Based Combination Treatment Dramatically Increases Therapeutic Efficacy in Murine Globoid Cell Leukodystrophy
Jacqueline A. Hawkins-Salsbury et al.
JOURNAL OF NEUROSCIENCE (2015)
Immune Responses to Intramuscular Administration of Alipogene Tiparvovec (AAV1-LPLS447X) in a Phase II Clinical Trial of Lipoprotein Lipase Deficiency Gene Therapy
Valerie Ferreira et al.
HUMAN GENE THERAPY (2014)
Plasmapheresis Eliminates the Negative Impact of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery
L. G. Chicoine et al.
MOLECULAR THERAPY (2014)
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
A. C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells
Ashley T. Martino et al.
BLOOD (2013)
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
D. Gaudet et al.
GENE THERAPY (2013)
Minimizing the Inhibitory Effect of Neutralizing Antibody for Efficient Gene Expression in the Liver With Adeno-associated Virus 8 Vectors
Jun Mimuro et al.
MOLECULAR THERAPY (2013)
Humoral immune response to AAV
Roberto Calcedo et al.
FRONTIERS IN IMMUNOLOGY (2013)
MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Muriel Sudres et al.
MOLECULAR THERAPY (2012)
Immune Responses to AAV in Clinical Trials
Federico Mingozzi et al.
CURRENT GENE THERAPY (2011)
Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors
Steven J. Gray et al.
HUMAN GENE THERAPY (2011)
Phase 2 Clinical Trial of a Recombinant Adeno-Associated Viral Vector Expressing α1-Antitrypsin: Interim Results
Terence R. Flotte et al.
HUMAN GENE THERAPY (2011)
A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8
Virginie Monteilhet et al.
MOLECULAR THERAPY (2011)
Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
Sylvie Boutin et al.
HUMAN GENE THERAPY (2010)
The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice
Jiangao Zhu et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses
Roberto Calcedo et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
Mark L. Brantly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Safety and efficacy of gene transfer for Leber's congenital amaurosis
Albert M. Maguire et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
Federico Mingozzi et al.
BLOOD (2007)
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy
Haiyan Jiang et al.
BLOOD (2006)
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice
CD Scallan et al.
BLOOD (2006)
Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response
CS Manno et al.
NATURE MEDICINE (2006)
AAV serotype 2 vectors preferentially integrate into active genes in mice
H Nakai et al.
NATURE GENETICS (2003)
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
F Mingozzi et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
分享论文
